ClinicalTrials.gg
RecruitingNCT06587698Updated Sep 19, 2024

Sitagliptin or BeiDouGen Capsule Improve the Pregnancy Outcome in Patients with PCOS

An interventional study of Sitagliptin and BeiDouGen in Polycystic Ovarian Syndrome, sponsored by Peking University Third Hospital. Recruiting at 1 site in China. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Peking University Third Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Polycystic Ovary Syndrome by Peking University Third Hospital — 7 open to participants now, 7 under way, none of them phase 3. Polycystic Ovary Syndrome · Peking University Third Hospital.

Planned enrollment
6th of 12
300 · median 255
Started
2024
with 1 other
No phase
11 of 13
6 open now
Registered
8th of 13
by date

Among the 13 studies in Polycystic Ovary Syndrome by Peking University Third Hospital, this one is the 6th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2024, is one of 11 with no phase, and was the 8th registered.

Polycystic Ovary Syndrome

959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

7 of the 13 studies in Polycystic Ovary Syndrome by Peking University Third Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 20 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Polycystic Ovary Syndrome by Peking University Third Hospital, or all of them as a file.
02

Study summary

This study will be carried out under the guidance of professional doctor, patients with PCOS will be treated with Sitagliptin or BeiDouGen capsule or both two to assess their ovarian function and reproductive outcomes, and compare the effect of different treatment methods, which will provide the basis for PCOS intervention strategy and related research

Read the detailed description

Subject Recruitment and Grouping This study adopts an open-label randomized controlled trial design. We plan to recruit a total of 300 patients with polycystic ovary syndrome (PCOS) by introducing the purpose, benefits, and risks of the study to patients in medical or examination units. PCOS patients who meet the inclusion criteria and do not meet the exclusion criteria will be registered and given a questionnaire by the research staff after signing the informed consent form. Physical and blood examinations will be conducted, and electronic randomization will be performed using the Redcap platform.

Intervention Measures After signing the informed consent form, enrolled patients will be randomly assigned to the Sitagliptin intervention group, the Bei Dou Gen intervention group, or the combination therapy group of Sitagliptin and Bei Dou Gen. Before enrollment, all three groups will undergo baseline assessments including blood routine, liver and kidney function, blood lipids, endocrine hormones, gynecological ultrasound, liver ultrasound, and physical examinations.

For participants in the Sitagliptin intervention group, Sitagliptin will be administered orally at a dose of 100 mg once daily for a treatment period of three months. Participants in the Bei Dou Gen intervention group will receive Bei Dou Gen capsules orally at a dose of 60 mg twice daily for a treatment period of three months. Participants in the combination therapy group will receive both Sitagliptin at a dose of 100 mg once daily and Bei Dou Gen capsules at a dose of 60 mg twice daily for a treatment period of three months.

03

Conditions studied

  • Polycystic Ovarian Syndrome
04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged 20-40 years who plan to conceive or are infertile in our center.

Diagnosed with PCOS according to the Rotterdam criteria: Diagnosis of PCOS can be made if two out of the following three criteria are met: (1) Oligoovulation or anovulation, (2) Clinical or biochemical signs of hyperandrogenism, (3) Polycystic ovaries on ultrasound examination.

Patients who are regularly followed up at our clinic. No participation in other research projects currently or in the past 3 months.

Exclusion criteria

Exclusion Criteria:

Exclusion criteria (any of the following criteria met will result in exclusion):

Pregnant, lactating, or women. Taking weight loss medications or undergoing weight loss surgery in the past 3 months or currently.

Food allergies. Other diseases that may cause hyperandrogenism or ovulation abnormalities (e.g., Cushing's syndrome, non-classical congenital adrenal hyperplasia, tumors secreting androgens in the ovaries or adrenal glands, functional hypothalamic amenorrhea, thyroid diseases, hyperprolactinemia, premature ovarian insufficiency, etc.).

Use of insulin, hypoglycemic drugs, or beta-blockers in the past 3 months. Patients with chronic diseases such as hypertension, gout, hyperuricemia, diabetes, etc., requiring regular medication.

Use of , anti-androgenic drugs, oral , ovulation-inducing drugs, weight loss drugs, or other medications affecting hormone levels, appetite, and carbohydrate metabolism in the past 2 months.

Patients with liver cirrhosis or various severe liver diseases ( and/or aspartate aminotransferase exceeding 3 times the ), patients with abnormal renal function (serum creatinine exceeding the upper limit of normal), patients with kidney disease or other diseases requiring control of protein intake.

Patients currently or previously with severe cardiovascular and cerebrovascular diseases that may interfere with the normal conduct of the trial (such as heart failure, myocardial infarction, cerebral infarction, acute myocarditis, severe arrhythmias, patients undergoing interventional therapy, etc.).

Patients currently with severe gastrointestinal diseases such as gastrointestinal ulcer bleeding, chronic diarrhea, or who have undergone gastrointestinal resection surgery, which may affect nutrient absorption.

Patients with infectious diseases such as e antigen-positive, active pulmonary tuberculosis, or .

Cancer patients or those who have received radiation and chemotherapy within the past five years.

Patients with any psychological or psychiatric disorders requiring medication, including epilepsy patients or those undergoing antiepileptic treatment, patients using antidepressants, etc.

Daily alcohol consumption exceeding 15g. Smoking habit

-

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Other
    Sitagliptin

    100mg/day Sitagliptin by oral for 3 months detail:1 piece(100mg) at morning

    Drug: Sitagliptin

  • Other
    BeiDouGen

    120mg/day BeiDouGen capsule by oral for 3 months detail:2 piece(30mg) at morning and night

    Drug: BeiDouGen

  • Other
    Sitagliptin+BeiDouGen

    100mg/day Sitagliptin+120mg/day BeiDouGen capsule by oral for 3 months detail:1 piece(100mg) Sitagliptin and 2 piece(30mg) BeiDouGen capsule at morning 2 piece(30mg) BeiDouGen capsule at night

    Drug: Sitagliptin+BeiDouGen

Interventions

  • 100 mg QD for 3 month

    Also known as: brand name:Jie Nuo Wei

  • DrugBeiDouGen

    60 mg BID for 3 month

    Also known as: brand name:Kang xin

  • DrugSitagliptin+BeiDouGen

    Drug page: SitagliptinStudies of SitagliptinSitagliptin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    100 mg Sitagliptin QD plus BeiDouGen 60 mg BID for 3 month

    Also known as: brand name:Jie Nuo Wei and Kang xin

06

What researchers measure

Primary outcomes

  1. Clinical pregnancy rate

    the pregnancy situation among volunteers

    Time frame: through study completion, an average of 2 year

Secondary outcomes

  1. DHEA

    dehydroepiandrosteron in serum during menstruation period

    Time frame: before and after intervention(3 month)

  2. total testosterone

    total testosterone in serum during menstruation period

    Time frame: before and after intervention(3 month)

  3. FAI

    Free testosterone index calculated by total testosterone and SHBG

    Time frame: before and after intervention(3 month)

  4. LH/FSH

    the rate between LH and FSH

    Time frame: before and after intervention(3 month)

  5. ovarian volume

    the size is measured by ultrasound

    Time frame: before and after intervention(3 month)

  6. number of antral follicles

    the number is is measured by ultrasound during menstruation period

    Time frame: before and after intervention(3 month)

  7. Number of retrieved eggs

    the number is observed during the surgery

    Time frame: after intervention(3 month)

  8. number of mature eggs (MII)

    observed the state of oocytes during the IVF laboratory

    Time frame: after intervention(3 month)

  9. fertilization rate

    observed the state of oocytes during the IVF laboratory

    Time frame: after intervention(3 month)

  10. number of usable embryos,

    observed the state of embryos during the IVF laboratory

    Time frame: after intervention(3 month)

  11. number of high-quality embryos

    observed the state of embryos during the IVF laboratory

    Time frame: after intervention(3 month)

  12. GLP-1 levels

    measure it in the serum

    Time frame: before and after intervention(3 month)

  13. fasting glucose

    measured by glucometer

    Time frame: before and after intervention(3 month)

  14. OGTT

    measured by glucometer

    Time frame: before and after intervention(3 month)

  15. HOMA index

    calculated by glucose and INS

    Time frame: before and after intervention(3 month)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jul 2028, 46 months after the start.

Of 205 non-industry interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 46 months is above that.

Counting every sponsor, half of 220 studies reached it within 17 months; a quarter within 7 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2024
First posted
Sep 19, 2024
StartActual
Aug 21, 2024
Primary completionEst.
Jul 1, 2028
CompletionEst.
Jul 1, 2029
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06587698
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Aug 21, 2024
Primary completion
Jul 1, 2028 (estimated)
Completion
Jul 1, 2029 (estimated)
Last update
Sep 19, 2024

Study contacts

Jie Qiao, PhD
Contact
myl1995lmy@163.com
15611555481
Jie Qiao
study chair · the third hospital of peking universry

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion